Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin with α-glucosidase inhibitor in Type 2 Diabetes
NCT01263483Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2007
- Primary completion
- Apr 2008
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of alogliptin in type 2 diabetes mellitus (T2DM), sponsored by Takeda. Started Jan 2007; status: completed.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01263483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01263483.